MichaelAPostowMD

PubMed

• 1 citations
  Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
  Georgina V Long, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Christopher D Lao
  Journal of Clinical Oncology. 2025-03-10
• IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies.
  Leah Gajecki, Irina V Lebedeva, Yu-Rou Liao, Daisy Ambriz, Lukas M Carter
  Journal of Nuclear Medicine. 2025-02-20
• Artificial Intelligence for Drug Discovery: An Update and Future Prospects.
  Harrison J Howell, Jeremy P McGale, Aurélie Choucair, Dorsa Shirini, Nicolas Aide
  Seminars in Nuclear Medicine. 2025-02-17

Journal Articles

• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain  
  Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
• Marked Response of a Hypermutated Adrenocorticotropic Hormone-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab  
  Michael Postow, Viviane Tabar, T Jonathan Yang, John Cuaron, Jinru Shia, Lisa M DeAngelis, The Journal of Clinical Endocrinology and Metabolism
• Melanoma Brain Metastases Treated with Stereotactic Radiosurgery and Concurrent Pembrolizumab Display Marked Regression; Efficacy and Safety of Combined Treatment  
  Jedd D Wolchok, Kathryn Beal, Yoshiya Yamada, Michael A Postow, BioMed Central

Lectures

• Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiotherapy (RT) in patients with metastatic melanoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Treatment of Advanced Melanoma After Progression on PD-1 Blockade 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Melanoma and Other Skin Cancers. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 1) 
  2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018